An observational study in Glucose Metabolism Disorders, sponsored by University Hospital, Gentofte, Copenhagen. Completed at 1 site in Denmark. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-09.
Sponsored by University Hospital, Gentofte, Copenhagen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Glucose Metabolism Disorders with a site in Denmark — 3 open to participants now, 4 under way, 1 of them phase 3. Glucose Metabolism Disorders · Denmark.
Among the 39 studies in Glucose Metabolism Disorders with a site in Denmark, this one is one of 6 that started in 2017, is one of 5 observational ones, and was the 18th registered.
361 studies on the registry are indexed under Glucose Metabolism Disorders; 38 are open to participants now.
Browse Glucose Metabolism Disorders studies →3 of the 39 studies in Glucose Metabolism Disorders with a site in Denmark are open now. Recruiting first, the newest first:
Ultragenyx Pharmaceutical Inc · Sites in Denmark, United States, Brazil and 6 more countries
Ages 2+
Hvidovre University Hospital · Sites in Denmark
Ages 18+ · Healthy volunteers
University Hospital, Gentofte, Copenhagen · Sites in Denmark
Ages 20–50 · Men only
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 29 Glucose Metabolism Disorders studies recruiting now, 9 (31%) set no upper age limit and 18 (62%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 7 · Phase 4 1
First in 2001; this study’s year is marked. 6 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 87 across 47 observational studies indexed under Glucose Metabolism Disorders.
Median enrollment 24 across the 34 interventional studies, 60 across the 5 observational. Of the 32 that completed or were terminated, 5 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 39 have an industry lead sponsor. The 10 most frequent:
University Hospital, Gentofte, Copenhagen is the lead sponsor of 162 studies on the registry; 11 are open to participants now.
University Hospital, Gentofte, Copenhagen has 9 studies filed under Glucose Metabolism Disorders — fewer than ten, so there is no comparison to draw.
1 of the studies in Glucose Metabolism Disorders with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06334172University Hospital, Gentofte, CopenhagenThe Role of Oxytocin in Regulating Blood Glucose | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 39 studies in Glucose Metabolism Disorders with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The effect of cholecystectomy on postprandial plasma GLP-1 responses (primary endpoint) and glucose metabolism will be evaluated in 30 patients planned to undergo elective laparoscopic cholecystectomy.
This is an observational, parallel-group study in 30 patients with gallstone disease and 10 healthy control subjects. In patients undergoing cholecystectomy a 4h-meal test (liquid mixed meal) will be conducted at baseline (1-2 weeks before surgery) and again within 4 weeks after the cholecystectomy. Healthy subjects will be submitted to a single 4h-meal test.
Secondary endpoints include changes in plasma glucose, insulin, glucagon, GIP, PYY, gastrin, CCK, fibroblast growth factor 19 (FGF-19) and bile acids. Furthermore, secondary endpoints include changes in gastric emptying (evaluated by the paracetamol method).
A healthy, normal weight population undergoing elective surgery because of gall stone disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy, normal weight patients (BMI\<27) undergoing elective cholecystectomy will have a meal test performed before and after surgery.
Procedure: cholecystectomy
Healthy matched controls will have one meal test performed.
elective cholecystectomy performed due to gallstones, cholecystitis or other non-malignant conditions and therefore done regardless of the protocol of this study.
Postprandial GLP-1 response
Gut derived hormone secretion after a 4 h meal test measured in pmol/liter
Time frame: 240 min
plasma glucose
measured in mmol/liter
Time frame: 240 min
gastric emptying
evaluated by the paracetamol method
Time frame: 240 min
Resting metabolic rate
evaluated by calorimetry
Time frame: 240 min
insulin
measured in pmol/liter
Time frame: 240 min
Glucagon
measured in pmol/liter
Time frame: 240 min
PYY
peptide YY, measured in pmol/liter
Time frame: 240 min
GIP
measured in pmol/liter
Time frame: 240 min
CCK
Cholecystokinin, measured in pmol/liter
Time frame: 240 min
FGF-19
Fibroblast growth factor 19, measured in ng/mL
Time frame: 240 min
Gastrin
measured in pmol/liter
Time frame: 240 min
Bile acids
measured in nmol/ml
Time frame: 240 min
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2017 to primary completion in Mar 2022, 52 months.
Of 23 observational studies under Glucose Metabolism Disorders, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 67. This study's 52 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Glucose Metabolism Disorders →
University Hospital, Gentofte, Copenhagen →